On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization